Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Study of Subcutaneous Immune Globulin (IgPro20) in Primary Immunodeficiency
2014-003609-14Phase 3
- Sponsor
- CSL Limited
- Start
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of immune serum globulin in Immunogenetic disorder, sponsored by CSL Limited. Primary endpoint: Median of the individual subject's rate of adverse events per infusion.
02
Drugs
immune serum globulin
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on 2014-003609-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003609-14.